Alzchem Reports Q3 2026 Results, Confirms Full-Year Guidance

Alzchem said rising material costs, depreciation and planned startup expenses affected third-quarter earnings. Higher costs for its planned US nitroguanidin plant have led to renegotiations with the US Department of Defense.